The start-up axxelera produces ultra-high-density peptide arrays: using patented manufacturing technology, 300,000 customer-definable peptides are synthesized on a 76 mm x 25 mm glass chip. Pharmaceutical researchers need these screening tools for researching diseases and developing new drugs.
The axxelera arrays provide 10 times more information than before and expand the range of applications to include cell and bacterial screening. The founders will sell the arrays directly, targeting research centers in particular. They also plan to offer a screening service as an information service, targeting mainly big pharma companies.
Dr. Clemens von Bojničić-Kninski, Lucas Reissenberger, Dr. Girish Shankara, Dr. Roman Popov